Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 12 of 12

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Assessment of Recruitment Rate	Evaluated monthly and at the end of recruitment (i.e., 2 years or once the final participant has completed the study)	Number of participants who were screened, deemed eligible, and subsequently enrolled. Three (3) participants during the parallel-group design phase withdrew after consent but before being randomized/receiving study treatments. No other participants withdrew during the study.	participants per month	MEAN
SECONDARY	Reduction in Pain Severity	Difference between baseline and 1 hour, 2 hours, and 48 hours post-intervention.	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	units on a scale	MEAN
SECONDARY	Number of Eligible Participants Who Are Screened, Enrolled, and Complete All Assessments	Evaluated monthly and at the end of recruitment (i.e., 2 years or once the final participant has completed the study)	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Global Impression of Change	Evaluated for each participant at 2-hours post-intervention, and 48-hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	participants	NUMBER
SECONDARY	Study Feedback From Participants and Staff	Participant feedback evaluated at 48 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	units on a scale	MEAN
SECONDARY	Number of Participants Reporting Pain Freedom	2 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Reporting Sustained Pain Freedom	48 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Numbers of Participants Reporting a Change in 4-point Pain Severity Scale Between Baseline and 2 Hours Post-intervention	2 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Reporting Sustained Pain Relief	48 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Reporting Adverse Events	Evaluated from time of intervention to 2 hours and 48 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Reporting Freedom From Most Bothersome Symptom	2 hours post-intervention	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Discharged From the Emergency Department With no Further Intervention	2 hours post-intervention (after last intervention, following ED discharge)	Treatment data are combined across phases, separated based on treatment given and time given to be consistent with how we specified results would be reported in the protocol (i.e., ...for both the initial assigned intervention and the crossover intervention where applicable). Participants who received SoC IV at crossover received REN initially, and vice versa. No participants received REN crossover treatment as they were well enough to go home after the initial IV treatment (as per protocol).	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05102591/outcomes

API reference For AI assistants